Role of different monoamine receptors controlling MK-801-induced release of serotonin and glutamate in the medial prefrontal cortex: Relevance for antipsychotic action

International Journal of Neuropsychopharmacology

Volumn 12, Issue 4, 2009, Pages 487-499

  López Gil, Xavier ^a,b   Artigas, Francesc ^a,b   Adell, Albert ^a,b  

^a INST D INVESTIGACIONS B   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE SALUD MENTAL CIBERSAM   (Spain)

Author keywords

1 adrenoceptor; 5 HT1A receptor; 5 HT2A receptor; Dopamine D 1 D2 receptors; MK 801

Indexed keywords

2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; ALPHA 1 ADRENERGIC RECEPTOR; DIZOCILPINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; ETICLOPRIDE; GLUTAMIC ACID; PRAZOSIN; RACLOPRIDE; REPINOTAN; SEROTONIN; SEROTONIN 1A RECEPTOR; SEROTONIN 2A RECEPTOR; VOLINANSERIN; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; AMINO ACID RECEPTOR BLOCKING AGENT; DIZOCILPINE MALEATE; GLUTAMATE RECEPTOR; NEUROLEPTIC AGENT; RECEPTOR;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG RECEPTOR BINDING; MALE; MICRODIALYSIS; MONOAMINE NERVE CELL; MONOAMINERGIC SYSTEM; NERVE CELL EXCITABILITY; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; PYRAMIDAL NERVE CELL; RAT; RECEPTOR AFFINITY; RECEPTOR BLOCKING; SEROTONIN RELEASE; ANIMAL; DRUG ANTAGONISM; DRUG POTENTIATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; METABOLISM; PHYSIOLOGY; WISTAR RAT;

ADRENERGIC ALPHA-AGONISTS; ANIMALS; ANTIPSYCHOTIC AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DIZOCILPINE MALEATE; EXCITATORY AMINO ACID ANTAGONISTS; GLUTAMIC ACID; MALE; MICRODIALYSIS; PREFRONTAL CORTEX; RATS; RATS, WISTAR; RECEPTOR, SEROTONIN, 5-HT1A; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTORS, ADRENERGIC, ALPHA-1; RECEPTORS, BIOGENIC AMINE; RECEPTORS, DOPAMINE D1; RECEPTORS, DOPAMINE D2; RECEPTORS, GLUTAMATE; SEROTONIN;

EID: 67649234061     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145708009267     Document Type: Article

References (81)

1. 1 receptor-mediated neurotransmission in the effects of clozapine on phencyclidine-induced acute increases in glutamate levels in the rat medial prefrontal cortex. Naunyn-Schmiedeberg's Archives of Pharmacology 374, 177-193.
2. Adams B, Moghaddam B (1998). Corticolimbic dopamine neurotransmission is temporally dissociated from the cognitive and locomotor effects of phencyclidine. Journal of Neuroscience 18, 5545-5554.
3. Adams BW, Moghaddam B (2001). Effect of clozapine, haloperidol, or M100907 on phencyclidine-activated glutamate efflux in the prefrontal cortex. Biological Psychiatry 50, 750-757.
4. Adell A, Celada P, Abellán MT, Artigas F (2002). Origin and functional role of the extracellular serotonin in the midbrain raphe nuclei. Brain Research. Brain Research Reviews 39, 154-180.
5. Ahlenius S (1999). Clozapine: dopamine D1 receptor agonism in the prefrontal cortex as the code to decipher a Rosetta stone of antipsychotic drugs. Pharmacology and Toxicology 84, 193-196.
6. Alsene KM, Carasso BS, Connors EE, Bakshi VP (2006). Disruption of prepulse inhibition after stimulation of central but not peripheral a-1 adrenergic receptors. Neuropsychopharmacology 31, 2150-2161.
7. Amargós-Bosch M, Adell A, Artigas F (2007). Antipsychotic drugs reverse the AMPA receptor-stimulated release of 5-HT in the medial prefrontal cortex. Journal of Neurochemistry 102, 550-561.
8. 1-adrenoceptors in the rat medial prefrontal cortex increases the local in vivo 5-hydroxytryptamine release: reversal by antipsychotic drugs. Journal of Neurochemistry 87, 831-842.
9. 2A receptors in pyramidal neurons of prefrontal cortex. Cerebral Cortex 14, 281-299.
10. Amargós-Bosch M, López-Gil X, Artigas F, Adell A (2006). Clozapine and olanzapine, but not haloperidol, suppress serotonin efflux in the medial prefrontal cortex elicited by phencyclidine and ketamine. International Journal of Neuropsychopharmacology 9, 565-573.
11. 1A receptors mediate opposing responses on membrane excitability in rat association cortex. Neuroscience 40, 399-412.
12. Arnt J, Skarsfeldt T (1998). Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology 18, 63-101.
13. 2A receptors in the rat medial prefrontal cortex: an iontophoretic study. Synapse 17, 173-181.
14. 2 receptors by antipsychotic drugs and novel compounds in the mouse striatum and olfactory tubercles. Naunyn-Schmiedeberg's Archives of Pharmacology 373, 441-450.
15. Assié MB, Ravailhe V, Faucillon V, Newman-Tancredi A (2005). Contrasting contribution of 5-hydroxytryptamine 1A receptor activation to neurochemical profile of novel antipsychotics: frontocortical dopamine and hippocampal serotonin release in rat brain. Journal of Pharmacology and Experimental Therapeutics 315, 265-272.
16. 1A serotonin receptor is located on calbindin- and parvalbumin-containing neurons in the rat brain. Brain Research 959, 58-67.
17. Beasley CL, Zhang ZJ, Patten I, Reynolds GP (2002). Selective deficits in prefrontal cortical GABAergic neurons in schizophrenia defined by the presence of calcium-binding proteins. Biological Psychiatry 52, 708-715.
18. Benes FM (1997). The role of stress and dopamine-GABA interactions in the vulnerability for schizophrenia. Journal of Psychiatric Research 31, 257-275.
19. Benes FM, Taylor JB, Cunningham MC (2000). Convergence and plasticity of monoaminergic systems in the medial prefrontal cortex during the postnatal period: implications for the development of psychopathology. Cerebral Cortex 10, 1014-1027.
20. Bergson C, Mrzljak L, Smiley JF, Pappy M, Levenson R, Goldman-Rakic PS (1995). Regional, cellular, and subcellular variations in the distribution of D1 and D5 dopamine receptors in primate brain. Journal of Neuroscience 15,7821-7836.
21. Bortolozzi A, Díaz-Mataix L, Toth M, Celada P, Artigas F (2007). In vivo actions of aripiprazole on serotonergic and dopaminergic systems in rodent brain. Psychopharmacology 191, 745-758.
22. Bymaster FP, Calligaro DO, Falcone JF, Marsh RD, Moore NA, Tye NC, Seeman P, Wong DT (1996). Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 14, 87-96.
23. 1A receptor agonist 8-OH-DPAT prevents prefrontocortical glutamate and serotonin release in response to blockade of cortical NMDA receptors. Journal of Neurochemistry 96, 853-860.
24. Callado LF, Hopwood SE, Hancock PJ, Stamford JA (2000). Effects of dizocilpine (MK 801) on noradrenaline, serotonin and dopamine release and uptake. NeuroReport 11, 173-176.
25. 2A receptors in the medial prefrontal cortex to different aspects of executive control such as impulsivity and compulsive perseveration in rats. Neuropsychopharmacology 31, 757-767.
26. Ceglia I, Carli M, Baviera M, Renoldi G, Calcagno E, Invernizzi RW (2004). The 5-HT2A receptor antagonist M100,907 prevents extracellular glutamate rising in response to NMDA receptor blockade in the mPFC. Journal of Neurochemistry 91, 189-199.
27. A, and glutamate receptors. Journal of Neuroscience 21, 9917-9929.
28. Cornea-Hébert V, Riad M, Wu C, Singh SK, Descarries L (1999). Cellular and subcellular distribution of the serotonin 5-HT2A receptor in the central nervous system of adult rat. Journal of Comparative Neurology 409, 187-209.
29. Czyrak A, Czepiel K, Mackowiak M, Chocyk A, Wedzony K (2003). Serotonin 5-HT1A receptors might control the output of cortical glutamatergic neurons in rat cingulate cortex. Brain Research 989, 42-51.
30. 1 receptor binding on pyramidal and nonpyramidal neurons. Synapse 28, 83-90.
31. 1d-adrenergic receptor mRNA in the rat brain and spinal cord. Journal of Chemical Neuroanatomy 13, 115-139.
32. 1A receptors in prefrontal cortex in the modulation of dopaminergic activity: role in atypical antipsychotic action. Journal of Neuroscience 25, 10831-10843.
33. 1A adrenergic receptor mRNA in the rat brain visualized by in situ hybridization. Journal of Comparative Neurology 386, 358-378.
34. Egan MF, Weinberger DR (1997). Neurobiology of schizophrenia. Current Opinion in Neurobiology 7, 701-707.
35. Gabbott PL, Warner TA, Jays PR, Salway P, Busby SJ (2005). Prefrontal cortex in the rat: projections to subcortical autonomic, motor, and limbic centers. Journal of Comparative Neurology 492, 145-177.
36. Gao WJ, Wang Y, Goldman-Rakic PS (2003). Dopamine modulation of perisomatic and peridendritic inhibition in prefrontal cortex. Journal of Neuroscience 23, 1622-1630.
37. Goff DC, Midha KK, Brotman AW, McCormick S, Waites M, Amico ET (1991). An open trial of buspirone added to neuroleptics in schizophrenic patients. Journal of Clinical Psychopharmacology 11, 193-197.
38. 1 receptor in schizophrenia: insights for cognitive dysfunction. Psychopharmacology 174, 3-16.
39. Grace AA (1991). Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia. Neuroscience 41, 1-24.
40. Grunze HC, Rainnie DG, Hasselmo ME, Barkai E, Hearn EF, McCarley RW, Greene RW (1996). NMDA-dependent modulation of CA1 local circuit inhibition. Journal of Neuroscience 16, 2034-2043.
41. Homayoun H, Moghaddam B (2007a). Fine-tuning of awake prefrontal cortex neurons by clozapine: comparison with haloperidol and N-desmethylclozapine. Biological Psychiatry 61, 679-687.
42. Homayoun H, Moghaddam B (2007b). NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons. Journal of Neuroscience 27, 11496-11500.
43. 1A receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release. Journal of Neurochemistry 76, 1521-1531.
44. Iravani MM, Muscat R, Kruk ZL (1999). MK-801 interaction with the 5-HT transporter: a real-time study in brain slices using fast cyclic voltammetry. Synapse 32, 212-224.
45. Jackson ME, Homayoun H, Moghaddam B (2004). NMDA receptor hypofunction produces concomitant firing rate potentiation and burst activity reduction in the prefrontal cortex. Proceedings of the National Academy of Sciences USA 101, 8467-8472.
46. Javitt DC, Zukin SR (1991). Recent advances in the phencyclidine model of schizophrenia. American Journal of Psychiatry 148, 1301-1308.
47. 2 occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. American Journal of Psychiatry 157, 514-520.
48. 2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. American Journal of Psychiatry 156, 286-293.
49. Kargieman L, Santana N, Mengod G, Celada P, Artigas F (2007). Antipsychotic drugs reverse the disruption in prefrontal cortex function produced by NMDA receptor blockade with phencyclidine. Proceedings of the National Academy of Sciences USA 104, 14843-14848.
50. Katayama T, Jodo E, Suzuki Y, Hoshino KY, Takeuchi S, Kayama Y (2007). Activation of medial prefrontal cortex neurons by phencyclidine is mediated via AMPA/kainate glutamate receptors in anesthetized rats. Neuroscience 150, 442-448.
51. Khan ZU, Gutiérrez A, Martín R, Peñafiel A, Rivera A, De La Calle A (1998). Differential regional and cellular distribution of dopamine D2-like receptors: an immunocytochemical study of subtype-specific antibodies in rat and human brain. Journal of Comparative Neurology 402, 353-371.
52. Krystal JH, D'Souza DC, Mathalon D, Perry E, Belger A, Hoffman R (2003). NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development. Psychopharmacology 169, 215-233.
53. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, Heninger GR, Bowers Jr. MB, Charney DS (1994). Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Archives of General Psychiatry 51, 199-214.
54. Langman NJ, Smith CG, Whitehead KJ (2006). Selective serotonin re-uptake inhibition attenuates evoked glutamate release in the dorsal horn of the anaesthetised rat in vivo. Pharmacological Research 53, 149-155.
55. Le Moine C, Gaspar P (1998). Subpopulations of cortical GABAergic interneurons differ by their expression of D1 and D2 dopamine receptor subtypes. Brain Research. Molecular Brain Research 58, 231-236.
56. López-Gil X, Babot Z, Amargós-Bosch M, Sunol C, Artigas F, Adell A (2007). Clozapine and haloperidol differently suppress the MK-801-increased glutamatergic and serotonergic transmission in the medial prefrontal cortex of the rat. Neuropsychopharmacology 32, 2087-2097.
57. Lorrain DS, Baccei CS, Bristow LJ, Anderson JJ, Varney MA (2003). Effects of ketamine and N-methyl-D-aspartate on glutamate and dopamine release in the rat prefrontal cortex: modulation by a group II selective metabotropic glutamate receptor agonist LY379268. Neuroscience 117, 697-706.
58. ° Lundberg T, Lindström L, Hartvig P, Reibring L, Agren H, Lundqvist H, Fasth KJ, Antoni G, Langström B (1996). Serotonin-2 and dopamine-1 binding components of clozapine in frontal cortex and striatum in the human brain visualized by positron emission tomography. Psychiatry Research (Neuroimaging Section) 67, 1-10.
59. 1-adrenoceptor activation induces excitatory postsynaptic currents in layer V pyramidal cells of the medial prefrontal cortex. European Journal of Pharmacology 367, 197-206.
60. Meltzer HY (2004). What's atypical about atypical antipsychotic drugs? Current Opinion in Pharmacology 4, 53-57.
61. 1A receptors. Journal of Pharmacology and Experimental Therapeutics 295, 853-861.
62. Millan MJ (2005). N-Methyl-D-aspartate receptors as a target for improved antipsychotic agents: novel insights and clinical perspectives. Psychopharmacology 179, 30-53.
63. 2A sites for PCP-induced locomotion in the rat. European Journal of Neuroscience 11, 4419-4432.
64. Moghaddam B, Adams B, Verma A, Daly D (1997). Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. Journal of Neuroscience 17, 2921-2927.
65. Moss LE, Neppe VM, Drevets WC (1993). Buspirone in the treatment of tardive dyskinesia. Journal of Clinical Psychopharmacology 13, 204-209.
66. 1 receptor agonism: an in vivo experimental study using core temperature measurements in the rat. Journal of Pharmacology and Experimental Therapeutics 292, 731-736.
67. Okubo Y, Suhara T, Suzuki K, Kobayashi K, Inoue O, Terasaki O, Someya Y, Sassa T, Sudo Y, Matsushima E, et al. (1997). Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET. Nature 385, 634-636.
68. Patil ST, Zhang L, Martenyi F, Lowe SL, Jackson KA, Andreev BV, Avedisova AS, Bardenstein LM, Gurovich IY, Morozova MA, et al. (2007). Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nature Medicine 13, 1102-1107.
69. Paxinos G, Watson C (1986). The Rat Brain in Stereotaxic Coordinates. San Diego: Academic Press.
70. Pehek EA, Yamamoto BK (1994). Differential effects of locally administered clozapine and haloperidol on dopamine efflux in the rat prefrontal cortex and caudate-putamen. Journal of Neurochemistry 63, 2118-2124.
71. 1 adrenoceptors in rat brain revealed by in situ hybridization experiments utilizing subtype-specific probes. Journal of Neuroscience 14, 4252-4268.
72. Rollema H, Lu Y, Schmidt AW, Zorn SH (1997). Clozapine increases dopamine release in prefrontal cortex by 5-HT1A receptor activation. European Journal of Pharmacology 338, R3-R5.
73. 2A receptors in pyramidal and GABAergic neurons of the rat prefrontal cortex. Cerebral Cortex 14, 1100-1109.
74. 2A receptor blockade. Journal of Pharmacology and Experimental Therapeutics 277, 1541-1549.
75. Seamans JK, Gorelova N, Durstewitz D, Yang CR (2001). Bidirectional dopamine modulation of GABAergic inhibition in prefrontal cortical pyramidal neurons. Journal of Neuroscience 21, 3628-3638.
76. Seamans JK, Yang CR (2004). The principal features and mechanisms of dopamine modulation in the prefrontal cortex. Progress in Neurobiology 74, 1-58.
77. Sesack SR, Hawrylak VA, Melchitzky DS, Lewis DA (1998). Dopamine innervation of a subclass of local circuit neurons in monkey prefrontal cortex: ultrastructural analysis of tyrosine hydroxylase and parvalbumin immunoreactive structures. Cerebral Cortex 8, 614-622.
78. 1A agonist, on memory function in schizophrenia. Biological Psychiatry 49, 861-868.
79. Svensson TH (2003). a-Adrenoceptor modulation hypothesis of antipsychotic atypicality. Progress in Neuro-psychopharmacology and Biological Psychiatry 27, 1145-1158.
80. 2 receptors in rat medial prefrontal cortex. Synapse 19, 112-120.
81. 2A receptors are expressed on pyramidal cells and interneurons in the rat cortex. Synapse 27, 79-82.